Introduction

The women’s healthcare market (including FemTech, diagnostics, therapeutics, devices, and related digital health) is in a period of rapid growth that warrants serious attention from fund managers and their limited partners. Whether you are a GP evaluating new deployment opportunities or an LP assessing a fund’s thematic allocation, signals in this space point toward underappreciated opportunity, growing demand, and favorable tailwinds — characteristics that align well with venture-stage fund strategies seeking outsized, risk-adjusted returns.

Current State of the Women’s Healthcare Market

To fully understand the unprecedented opportunity this space presents to VC, it’s critical to understand the current state of the market and trend developments over recent years.

Key Data & Market Information

• The global women’s health market was estimated at approximately $49.33 billion in 2024 and $53.48 billion in 2025, with forecasts putting it at $75.42 billion by 2033 (CAGR ~5.1%) across categories like contraceptives, menopause, hormonal therapies, etc.[1]
• The therapeutics for women’s health technologies alone are projected to grow from $61.5 billion (2024) to $81.2 billion by 2029, at ~5.7% CAGR.[2] The women’s health devices sector is even more aggressive: valued at $55.45 billion in 2025, expected to reach $115.64 billion by 2034, with a CAGR of ~10.03%.[3] 
  • Diagnostics is growing fast: the women’s health diagnostics market is estimated to be worth $32.68 billion in 2026, and moving toward $44.42 billion by 2031, at ~6.33% CAGR.[4] Within the women’s health diagnostics market, diagnostic tests occupied 54.21% of the market, and genetic and genomic panels are projecting a 9.10% CAGR through 2031.[5]
  • There is a major demand for devices in home healthcare, reproductive health, and chronic disease monitoring, etc. 
  • Digital health is estimated to reach $6.4 billion by 2030, with projected growth well above many traditional healthcare categories. 

Investment Volume and Funding Trends

• Aggregate investment in women’s health reached $2.6 billion in 2024, nearly $1 billion more than the previous year — a 55% year-over-year increase, far outpacing growth in the broader healthcare industry.[6] When including health conditions that disproportionately affect women (though not always categorized strictly under “women’s health”), the figure jumps to $10.7 billion in 2024.[7] 
• Over the past few years, there has been a notable funding stage shift. Earlier years saw a preponderance of Series Seed and Series A deals in women’s health, but as of 2024, funding is beginning to be spread across financing rounds that more closely mirrors the wider healthcare industry. For example, in 2023, Series Seed and Series A rounds comprised 83% of women’s healthcare deals (versus 72% of the deals in the wider healthcare industry), whereas in 2024, such deals comprised 70% of women’s healthcare deals (versus 67% of the deals in the wider healthcare industry).[8]
• Even as investment in women’s health rises in absolute dollars, its share of total healthcare VC dollars remains low. For example, women’s health companies (which include companies whose technology is defined as falling within the reproductive or FemTech verticals) in a given year received only ~2.3% of all healthcare VC funding, down from ~4.1% in a past benchmark year.[9] Moreover, even when taking a broader definition of women’s health companies (i.e., including companies whose technology also applies to conditions that disproportionately or differently affect women), the percentage rises to just 6%.[10] Given that women comprise approximately 50% of the world’s population, this statistic is staggering.

Future Growth Drivers

The momentum in women’s healthcare will only accelerate in the future for the following reasons:

• Aging Female Population. By 2030, 1 in 6 people worldwide will be aged 60 or over, and the share of the population aged 60 and over will increase from 1 billion in 2020 to 1.4 billion.[11] This demographic shift drives demand for osteoporosis treatments, menopausal therapies, and cardiovascular health products.[12] Maven Clinic’s Menopause & Midlife program experienced 300% year-over-year growth in 2023-2024.[13]
• Evergreen Opportunities for Maternal and Newborn Care. Approximately 370,000 women give birth worldwide every day.[14] Maven Clinic’s Maternity & Newborn Care program experienced more than 400% client growth in the year preceding its Series F round (2023-2024).[15] Particularly within the United States, where the maternal mortality rate remains notably high among high-income nations (the U.S. is ranked 62^nd globally based on data for 2023 at 18.6 per 100,000 live births),[16] improving the lives of those within this evergreen population is a huge opportunity for VC investment.
• Rising Prevalence of Chronic and Reproductive Conditions. The increasing incidence of hormone-dependent chronic diseases such as polycystic ovarian syndrome (PCOS), endometriosis, and osteoporosis requires lifelong management and specialized therapeutic interventions.[17] Endometriosis impacts approximately 10% of women of reproductive age worldwide.[18]
• Massive Underdiagnosis and Undertreatment Gap. Proper screening and better care for U.S. women across four common conditions (menopause, osteoporosis, Alzheimer's, cardiovascular disease) represents an opportunity of more than $100 billion.[19] The menopause market could increase eightfold to more than $40 billion by 2030.[20] The osteoporosis market could grow from $5 billion to $27 billion.[21] Only 1 in 4 women currently treat menopause-related symptoms.[22] Two-thirds of women with osteoporosis remain undiagnosed.[23]
• Digital Health and Telehealth Expansion. The growth of digital health solutions, telemedicine, wearable devices, and women's health apps is a key accelerant.[24] In 2025, there were 1.2 billion women's healthcare visits, and a key driver of these increasing visits was telehealth services.[25]
• Innovation in Therapeutics and Diagnostics. Advancements include non-hormonal therapies for menopause and endometriosis, precision medicine for PCOS, AI-enhanced diagnostics for early cancer detection, and novel non-invasive surgical options for fibroids.[26]
•  Government Initiatives and Policy Support. Government-backed programs targeting maternal health, fertility access, and cancer screening are expanding the addressable market, particularly in emerging economies.[27] The World Health Organization continues to emphasize sexual and reproductive health as foundational to health system resilience.[28]
• Growing Investment and Strategic M&A. The women's health sector has tracked more than $100 billion in exits since the year 2000, with $27 billion transactions, demonstrating it is a proven, scaled investment category.[29] Strategic acquirers like Hologic (22 acquisitions) and CooperSurgical (21 acquisitions) demonstrate sustained long-term commitment.[30] Nearly half of all exits occurred in the past five years.[31]

GPs and LPs Should Concern Themselves with Fund-Level Allocation to Women’s Healthcare

Women’s healthcare presents a significant opportunity for VCs to tap into a largely untapped and high-growth market. GPs should be building conviction toward capital deployment in this space, and LPs should be asking questions about exposure to this sector, for the following reasons.

• Under-market saturation and deployment opportunity: Despite the market’s size, women’s health remains underinvested relative to its population, relevance, and demand. For GPs, that means numerous white-space opportunities and first-mover advantages in areas like menopause care, diagnostics for underdiagnosed female diseases, and fertility tech. For LPs, it signals that funds with a thesis here may access deal flow with less competition and more attractive entry valuations.
• Portfolio diversification across sub-sectors: The market isn’t monolithic. Diagnostics, digital health, therapeutics, and devices each carry different risk-reward profiles. GPs can construct diversified portfolios across these segments to mitigate concentration risk (e.g., pairing device innovations with digital platform bets), and LPs evaluating a fund’s portfolio mix should look for this kind of sub-sector diversification as a mark of disciplined fund management.
• Regulatory and policy tailwinds supporting fund deployment: Increasing awareness among regulators and funders — both public and private (e.g., philanthropic pledges) align with growing demand. Large commitments (such as the Melinda French Gates-backed $100 million partnership between Pivotal and Wellcome Leap) suggest more grant and non-dilutive capital will support R&D, effectively de-risking early-stage portfolio companies. GPs should factor this into underwriting, and LPs can take comfort that policy momentum is working in the sector’s favor.
• Exit potential and return pathways: Companies like Maven Clinic reaching unicorn valuations ($1.7 billion at the time of its Series F round in 2024) and increasing biopharma investment in women’s health therapeutics indicate that exit pathways — acquisition and IPO — are becoming more credible and impressive. For GPs building toward DPI and fund-level returns, and for LPs evaluating a fund’s path to liquidity, this maturation is a meaningful signal.
• Maturing risk profile and stage progression: The shift from seed-heavy to more later-stage rounds in women’s health suggests sector maturation. For GPs, this creates opportunities to deploy across the risk spectrum — from early-stage conviction bets to later-stage, de-risked growth investments. LPs in funds with flexible mandates should view this positively, as it expands the investable universe within the theme.

Challenges and Key Risk Factors for GPs and LPs

• Definition and category ambiguity: Many companies serving diseases that disproportionately affect women are not coded as “women’s health,” which can make tracking, benchmarking, and market sizing harder. GPs should be prepared for definitional challenges in sourcing and categorizing deals, and LPs reviewing portfolio reporting should expect that fund exposure to the theme may not always map neatly to standard industry classifications.
• Regulatory and reimbursement risk: As with all healthcare and therapeutics, navigating FDA (or other jurisdictions), reimbursement, and clinical validation will remain high-cost and long lead-time. GPs must underwrite these timelines into fund models, and LPs should assess whether a fund’s reserve strategy and fund life accommodate these longer development cycles.
• Privacy and data security concerns: FemTech apps and digital platforms often collect sensitive health data. Recent studies show vulnerabilities in privacy and third-party tracking in many female health applications. GPs should insist on high compliance and strong data governance as a condition of investment, and LPs should ask about a fund’s ESG and data-risk diligence protocols in this area.
• Exit scarcity in some sub-sectors: Some areas (especially digital health) may have fewer exits relative to investment volume. GPs should prioritize companies with strong unit economics and clear paths to profitability, while LPs should evaluate whether the fund’s portfolio has sufficient diversification to avoid overconcentration in exit-constrained segments.

Overcoming Challenges and Key Risk Factors

Below are tactical considerations for GPs looking to build or increase fund-level exposure to women’s healthcare, and for LPs evaluating funds with this thesis.

• Deploy capital early but with rigorous diligence — particularly in therapeutic R&D, diagnostics, or device areas where technical validation is essential. LPs should look for GPs who bring deep healthcare networks and clinical advisory boards to their diligence process.
• Partner with experienced operators in women’s health; domain expertise (clinical, regulatory) matters more than in many other tech verticals. GPs building a women’s health allocation should consider venture partners, advisors, or co-investment relationships that bring sector-specific credibility. LPs should view strong operator networks as a differentiator during fund diligence.
• Leverage mixed funding models. Grants, non-dilutive funding, and public-private collaborations can de-risk early-stage portfolio companies and extend runway without additional dilution. GPs who can help portfolio companies access these sources create value; LPs benefit from reduced capital at risk in earlier stages.
• Focus on underserved populations and global markets. Many women in low- and middle-income regions are underserved, and scalable digital or diagnostic solutions can deliver impact and profit. For funds with an impact mandate or ESG lens, this sub-theme can serve double duty — generating returns while meeting LP impact objectives.
• Ensure data and privacy safeguards are embedded from the start. These should not be afterthoughts — especially for platforms collecting reproductive or menstrual health data. GPs should make this a standard diligence item, and LPs should expect reporting on data governance across the portfolio.

Conclusion

The women’s healthcare market is no longer a niche — it is a mainstream venture opportunity that both GPs and LPs would be imprudent to ignore. The data points to significant growth, existing underinvestment, sizable unmet needs, and increasing investor and policy support. GPs should view it as an incredible opportunity to build differentiated fund positions in a sector where competition remains manageable and the return potential is compelling. LPs should inquire whether their fund managers have the thesis, diligence capability, and operator networks to capture this opportunity. Those fund stakeholders willing to move thoughtfully — doing rigorous diligence, planning for regulatory and reimbursement demands, and balancing risk across sub-sectors — stand to generate strong returns alongside meaningful societal impact directly touching the lives of nearly half of the world’s population.

---